Prostate Cancer Clinical Trials in Georgia

Georgia's Online Cancer Information Center


back

Prostate Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Prostate Cancer
Cancer Type = Prostate Cancer
NCI ID Cancer Type Trial Name
There are currently 50 active Prostate Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06925737
Protocol IDs
2400-001
NCI-2025-03471
2024-517423-40
2024-517423-40-00
MK-2400-001
U1111-1312-2498
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
2.
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT06516510
Protocol IDs
BET-PSMA-001
NCI-2024-09547
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT07543055
Protocol IDs
BPX-601-PSA-2540
NCI-2026-06250
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
5.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
6.
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06842498
Protocol IDs
FGCL-3246-112
NCI-2025-01692
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
7.
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06095089
Protocol IDs
CR109330
NCI-2023-09674
2023
2023-504063-17-00
87189401PCR1001
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
8.
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Cancer Type
Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCT ID
NCT06465069
Protocol IDs
18882
NCI-2024-07005
2024-512927-36-00
J5I-OX-JZYA
LOXO-LNC-24001
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
9.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCT ID
NCT06238479
Protocol IDs
LOXO-ENC-23001
NCI-2024-02612
2023-509867-26-00
J5A-OX-JZWA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
10.
NCORP Trial
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06136650
Protocol IDs
5684-004
NCI-2024-01655
2023-504957-11
jRCT2031240030
MK-5684-004
U1111-1288-5002
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
11.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT07225946
Protocol IDs
78278343PCR3003
NCI-2025-09042
2025
2025-522713-29-00
78278343PCR3003
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
12.
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
13.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT07213674
Protocol IDs
20230239
NCI-2025-07528
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
14.
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06764485
Protocol IDs
CA071-1000
NCI-2025-02219
2024-517422-25
U1111-1311-0532
15.
An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT05779943
Protocol IDs
RAD5689-22-BED-IIT-439
NCI-2023-01322
STUDY00004720
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
16.
An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy using TRUS-MR Fusion Technique
Cancer Type
Prostate Cancer
NCT ID
NCT06865768
Protocol IDs
WINSHIP6265-24
NCI-2025-00207
STUDY00007915
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
17.
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT07206056
Protocol IDs
CDZR123A12107
NCI-2025-08418
2025-521880-10-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
18.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
19.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
20.
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03678025
Protocol IDs
S1802
S1802
NCI-2018-01738
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
21.
EDRN Prostate MRI Biomarker Study
Cancer Type
Prostate Cancer
NCT ID
NCT03784924
Protocol IDs
430
NCI-2020-13734
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
22.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03322891
Protocol IDs
HU-HEALTHLITERACY
NCI-2018-00842
IRB00091879
IRB00085616
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Grady Memorial Hospital
Atlanta
23.
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Cancer Type
Prostate Cancer
NCT ID
NCT06262139
Protocol IDs
MT218-002
NCI-2024-04399
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
24.
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Cancer Type
Bone Tumor, Breast Cancer, Lung Cancer, Prostate Cancer
NCT ID
NCT00882609
Protocol IDs
AMI-2008-01
Treatment Sites (1)
Southcoast Health
Savannah
25.
Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03762759
Protocol IDs
RAD4516-18
NCI-2018-02702
IRB00106863
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Grady Memorial Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
26.
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type
Prostate Cancer
NCT ID
NCT03151629
Protocol IDs
c16-170
NCI-2017-01549
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
27.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT05803941
Protocol IDs
CAAA617A12402
NCI-2023-08714
2023-503208-94-00
28.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (16)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
29.
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06780670
Protocol IDs
CAAA817A12201
NCI-2025-05946
2024-512342-42-00
30.
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT04421222
Protocol IDs
EPI-7386-CS-001
NCI-2020-11720
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
31.
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT04848337
Protocol IDs
HCRN GU19-385
NCI-2021-06868
32.
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Cancer Type
Prostate Cancer
NCT ID
NCT04995198
Protocol IDs
c19-235
NCI-2022-01764
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
33.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
34.
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06074510
Protocol IDs
PYL4301
NCI-2024-00237
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
35.
Radiation Therapy Alone, Radiation Therapy plus Leuprolide, or Radiation Therapy plus Relugolix for the Treatment of Non-metastatic Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT05320406
Protocol IDs
RAD5484-21
NCI-2022-00117
STUDY00003654
36.
Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06105918
Protocol IDs
RAD5633-23
NCI-2023-03480
STUDY00005677
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
37.
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Cancer Type
Prostate Cancer
NCT ID
NCT02744287
Protocol IDs
BP-012
NCI-2019-02615
38.
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Cancer Type
Breast Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Plasma cell neoplasm, Prostate Cancer
NCT ID
NCT06582017
Protocol IDs
QXL138AM-001
NCI-2024-07730
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
39.
Soccer-Based Lifestyle in Improving Bone and Metabolic Health in Prostate Cancer Survivors
Cancer Type
Prostate Cancer
NCT ID
NCT04144127
Protocol IDs
RSPH4684-19
NCI-2019-05183
IRB00110890
40.
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06855277
Protocol IDs
CAAA817B12301
NCI-2025-06540
2024-512340-32
2024-512340-32-00
41.
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCT ID
NCT04221542
Protocol IDs
20180146
NCI-2020-00424
2021-005052-11
2023-504361-23
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
42.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06267729
Protocol IDs
D9660C00001
NCI-2024-01754
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
43.
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04428788
Protocol IDs
CC-94676-PCA-001
NCI-2020-13275
U1111-1251-9174
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
44.
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05946213
Protocol IDs
NRG-GU013
NRG-GU013
NCI-2023-04142
Treatment Sites (4)
Emory Proton Therapy Center
Atlanta
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
45.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04134260
Protocol IDs
NRG-GU008
NRG-GU008
NCI-2019-06838
46.
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Cancer Type
Prostate Cancer
NCT ID
NCT05053152
Protocol IDs
NRG-GU011
NRG-GU011
NCI-2021-09164
Treatment Sites (1)
Piedmont Columbus Regional
Columbus
47.
NCORP Trial
Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04513717
Protocol IDs
NRG-GU009
NCI-2020-04705
NRG-GU009
Treatment Sites (3)
Bluffton Campus at St. Joseph's/Candler
Bluffton
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
St. Joseph's /Candler Health System, INC
Savannah
48.
NCORP Trial
Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05050084
Protocol IDs
NRG-GU010
NCI-2021-08760
NRG-GU010
49.
Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05445609
Protocol IDs
WINSHIP5576-22
NCI-2022-05290
STUDY00004226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
50.
Vudalimab in Combination with Standard of Care Treatment in Patients with Metastatic Castration Sensitive Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05733351
Protocol IDs
WINSHIP5741-22
NCI-2023-00171
STUDY00004688
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

 

Georgia CORE reduces the burden of cancer in our state through research, education, and advocacy.